Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellgram-DC-WT1 and Pembrolizumab in Metastatic Pancreatic Cancer
NCT06172634Phase 2Not yet recruiting
- Sponsor
- Soonchunhyang University Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Phase 2, open-label, single-arm trial of Cellgram-DC-WT1 in pancreatic cancer (PC), sponsored by Soonchunhyang University Hospital. Primary endpoint: Treatment Related Adverse Event at 1 year. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
Cellgram-DC-WT1
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06172634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06172634.